Psoriasis Treatment Market Market Analysis

In recent years, the South American psoriasis treatment landscape has undergone a significant transformation, particularly between 2023 and 2025. Historically dominated by topical corticosteroids and conventional systemic therapies like methotrexate and cyclosporine, the market has seen increasing integration of biologics and biosimilars. In Brazil, the Ministry of Health’s 2024 update to the Clinical Protocol and Therapeutic Guidelines for Psoriasis expanded access to biologics such as adalimumab, secukinumab, and ustekinumab for severe cases, reflecting a growing commitment to evidence-based care. Argentina’s dermatology network, led by specialists like Dr. Mariana Larramendi from Hospital Alemán, reported a 2024 multicenter study demonstrating improved patient adherence and quality-of-life scores with IL-23 inhibitors. Meanwhile, in Chile, a 2023 survey by Clínica Alemana highlighted that although biologic therapies are increasingly prescribed in metropolitan centers, public system limitations continue to restrict nationwide access. Colombia and Mexico similarly reported the 2024 introduction of biosimilars for anti-TNF agents, enabling wider availability in public hospitals, yet disparities remain between urban and rural areas. At the regulatory level, agencies such as ANVISA and COFEPRIS accelerated approvals of biosimilar and next-generation biologics, reflecting a regional push to balance innovation with cost-effectiveness. Complementing these advances, the International Psoriasis Council Latin America Working Group, with experts like Dr.

André Carvalho in Porto Alegre and Dr. Claudia de la Cruz in Santiago, strengthened regional knowledge-sharing and standardized clinical guidance, marking a clear shift toward modernized, patient-centered treatment approaches. These developments illustrate a recent evolution in South America, from conventional therapy reliance to more sophisticated biologic and biosimilar use, while highlighting persistent challenges in equitable access and long-term treatment monitoring. According to the research report, "South America Psoriasis Treatment Market Research Report, 2031," published by Actual Market Research, the South America Psoriasis Treatment market is expected to reach a market size of USD 2.14 Billion by 2031.The South American psoriasis treatment ecosystem is increasingly shaped by a complex interplay of healthcare providers, policymakers, pharmaceutical companies, and patient advocacy groups. In 2023–2025, dermatologists in major cities such as São Paulo, Buenos Aires, and Santiago have actively adopted IL-17 and IL-23 inhibitors, guided by real-world evidence from registries like the Brazilian Psoriasis Registry (BRES), which tracks treatment outcomes and adverse events for both biologics and biosimilars. Pharmaceutical manufacturers, including Janssen, Novartis, and AbbVie, have expanded partnerships with local distributors to facilitate supply chain reliability, while public programs such as Brazil’s CEAF and Colombia’s POS coverage schemes have gradually integrated newer therapies, providing a framework for reimbursement despite persistent budget constraints. Observational studies during this period highlighted patient adherence challenges linked to dosing frequency and the need for physician-patient education on long-term safety monitoring, particularly for immunomodulatory therapies. Clinical centers, including Clínica Las Condes in Santiago and Hospital Israelita Albert Einstein in São Paulo, have reported increased teledermatology utilization during follow-up consultations, enabling more consistent disease monitoring for moderate-to-severe patients. Recent Latin American guideline updates in 2024 emphasized the importance of personalized treatment selection based on comorbidities, genetic markers, and disease severity, reflecting the trend toward precision medicine. Additionally, local research collaborations and multicenter studies, such as those coordinated under the Global Psoriasis Atlas, have highlighted unmet needs, particularly in rural areas where access to specialty care is limited.

Regulatory refinements by ANVISA and COFEPRIS in 2024–2025 have also facilitated biosimilar approvals and strengthened pharmacovigilance reporting, encouraging manufacturers to expand their portfolios in the region. .

Market Dynamic

Psoriasis Treatment MarketSegmentation

Plaque psoriasis is the fastest growing type in the South America psoriasis treatment market due to its higher prevalence and significant impact on patients’ quality of life.

Plaque psoriasis, the most common form of psoriasis, is highly prevalent across South America, affecting a large portion of the population with visible, chronic symptoms. This form of psoriasis presents as raised, red patches covered with silvery-white scales, often found on the elbows, knees, and scalp. Its higher incidence in South America, particularly in countries like Brazil and Argentina, is due to genetic predispositions combined with environmental triggers like the tropical climate, which can exacerbate the condition. The severity of plaque psoriasis often leads patients to seek medical care more frequently, driving the demand for effective treatment options. Over the years, advancements in biologic therapies have significantly improved outcomes for patients with moderate-to-severe plaque psoriasis, especially with IL-17 and IL-23 inhibitors becoming more widely available. Additionally, societal awareness of chronic conditions like plaque psoriasis has grown, which, in turn, has led to more patients seeking treatment earlier in the disease process. With increased access to healthcare and diagnostic services, as seen in countries with improved public health systems like Brazil, the diagnosis and treatment of plaque psoriasis have become more efficient, accelerating its market growth. The rise of biologic treatments and improved patient education regarding treatment adherence also contribute to this upward trend. Furthermore, the social impact of visible skin conditions in the workplace and social settings has led to a higher demand for therapies that manage the disease effectively and improve overall quality of life, fueling the continued growth of plaque psoriasis treatments in the region.

TNF inhibitors remain a significant drug class in the South America psoriasis treatment market due to their long-established efficacy and availability in the region.

TNF inhibitors have become a cornerstone in the treatment of moderate-to-severe psoriasis across South America, especially because they have been available in the region for over a decade. Drugs like infliximab, adalimumab, and etanercept are widely used in clinical settings due to their strong track record in reducing inflammation, managing flare-ups, and providing long-term disease control. The relatively broad availability of TNF inhibitors has made them a first-line treatment for many patients with chronic psoriasis, especially those who do not respond well to topical therapies or phototherapy. Their long-established use in the region, combined with their clinical success, has made TNF inhibitors an integral part of the South American psoriasis treatment market. In countries like Brazil and Argentina, where public health systems have adopted these therapies in hospital formularies, patients benefit from state-supported access to these drugs, reducing financial barriers for treatment. The presence of generic TNF inhibitors in the market has also expanded accessibility, making these biologics more affordable for a larger patient pool, thus maintaining their prominence in treatment guidelines. Furthermore, TNF inhibitors’ ability to target tumor necrosis factor-alpha, a key protein in the inflammatory process of psoriasis, continues to make them a preferred choice for doctors managing severe cases. Despite the increasing uptake of newer biologics, TNF inhibitors remain significant in treating patients who may not yet have access to the latest therapies, as well as those who respond best to this class.

Systemic drugs are significant in the South America psoriasis treatment market due to their efficacy in treating moderate-to-severe cases of psoriasis and wider availability.

Systemic drugs, including traditional options like methotrexate, cyclosporine, and acitretin, continue to be a significant part of the treatment landscape in South America. Despite the growing popularity of biologic therapies, systemic treatments remain a primary choice for many patients with moderate-to-severe psoriasis, especially due to their cost-effectiveness and availability in both private and public healthcare systems. In countries like Brazil and Colombia, methotrexate is commonly prescribed as an initial systemic therapy, often as a first-line treatment before considering biologics. This is largely due to its broad availability, lower cost, and established safety profile. Systemic drugs also offer advantages for patients with extensive psoriasis lesions or those who fail to respond to topical therapies. The importance of systemic drugs is further underscored by the fact that many healthcare systems in South America, particularly in public settings, still face challenges in providing advanced biologic treatments due to high costs. As a result, systemic drugs remain essential for bridging the treatment gap and ensuring that patients receive effective care, even when access to biologics is limited. Moreover, the combination of systemic drugs with other treatment modalities such as phototherapy or topical agents is a common strategy in South America, making them an integral part of the psoriasis treatment framework in the region.

Injectables dominate the mode of administration in the South America psoriasis treatment market due to their targeted delivery and proven effectiveness.

Injectable therapies, especially biologics such as adalimumab, secukinumab, and ustekinumab, are becoming increasingly popular in South America due to their ability to deliver targeted treatment directly to the affected areas, offering superior control over psoriasis symptoms. Unlike oral drugs, which require absorption through the digestive system, injectables provide a more direct and efficient delivery, leading to quicker and more sustained therapeutic responses. As the prevalence of moderate-to-severe psoriasis continues to rise in South America, the demand for injectable treatments has increased, particularly in countries with well-developed healthcare infrastructure like Brazil and Argentina. These therapies are often preferred for their high efficacy in managing the chronic nature of the disease, offering long-lasting results for patients who may have struggled with less effective treatments. Furthermore, the patient-friendly administration methods, such as subcutaneous injections, have made injectables more accessible. In many cases, patients can administer these drugs themselves at home, reducing the burden on healthcare systems and improving adherence. The growth of injectable biologics has been particularly notable in South American countries where private healthcare options are readily available and where patients are increasingly seeking higher-quality, more effective treatments. The significant role of injectables in the psoriasis treatment market is expected to continue as more biologics and biosimilars enter the market, offering increased treatment options for patients across the region.

e-Commerce is the fastest growing distribution channel in the South America psoriasis treatment market due to increasing consumer demand for convenience and accessibility.

The rise of e-commerce has revolutionized how patients in South America access psoriasis treatments, particularly for over-the-counter (OTC) products and prescription medications. The increasing penetration of the internet and mobile devices has made it easier for patients to purchase topical treatments, supplements, and even certain biologics online. This is especially beneficial for those living in rural or remote areas, where access to physical pharmacies or healthcare centers may be limited. As more patients turn to the internet for healthcare solutions, e-commerce platforms have provided a valuable channel for obtaining essential psoriasis treatments without the need for in-person visits. Online sales also cater to the growing demand for convenience, allowing patients to order medications at their own pace and have them delivered directly to their homes. In addition, e-commerce platforms offer greater access to a range of products, from topical corticosteroids to alternative natural remedies, providing more choices for patients who may not have access to these options locally. As trust in online healthcare transactions grows and digital platforms improve their offerings, e-commerce is expected to continue its rapid rise as a primary method for distributing psoriasis treatments in South America, supporting the market's accessibility and reach.

Psoriasis Treatment Market Market Regional Insights

Brazil is leading the South America psoriasis treatment market due to its advanced healthcare system, large population, and increasing awareness of psoriasis.

Brazil is the leading region in the South American psoriasis treatment market primarily due to its extensive healthcare infrastructure, large population, and government-backed initiatives to improve disease management. The country has made significant strides in improving access to dermatological care, with public health programs offering broad coverage for psoriasis treatments, including biologics, to patients in both urban and rural areas. Brazil’s Unified Health System (SUS) plays a pivotal role in providing affordable treatment options to a vast majority of the population, which has led to improved disease outcomes. Additionally, the country’s large and diverse population, coupled with rising awareness about psoriasis, has resulted in more patients seeking effective treatments. Dermatologists in Brazil are increasingly adopting advanced therapies like biologics, leading to a steady rise in the demand for modern treatments. Furthermore, Brazil's role as a regional hub for pharmaceutical companies has attracted major investments in psoriasis care, with several multinational companies establishing a strong presence in the market. The country’s growing middle class is also contributing to the increasing preference for higher-quality treatments, including biologics and advanced systemic therapies. As a result, Brazil continues to be the dominant player in the South American psoriasis treatment market, with strong growth prospects driven by both public and private sector investments in healthcare infrastructure.